DB
AXSM icon

Dmitry Balyasny’s Axsome Therapeutics AXSM Stock Holding History

Dmitry Balyasny’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.7M Buy
+76,250
New +$16.5M 0.02% 753
2025
Q2 		– Sell
-24,431
Closed -$2.59M – 2818
2025
Q1 		$2.85M Sell
24,431
-156,782
-87% -$17.9M ﹤0.01% 1521
2024
Q4 		$15.3M Buy
181,213
+119,046
+191% +$10.9M 0.02% 777
2024
Q3 		$5.59M Buy
+62,167
New +$5.43M 0.01% 1203
2024
Q2 		– Sell
-9,606
Closed -$767K – 2568
2024
Q1 		$767K Buy
+9,606
New +$806K ﹤0.01% 1903
2023
Q1 		– Sell
-120,874
Closed -$9.32M – 2643
2022
Q4 		$9.32M Buy
+120,874
New +$7.22M 0.03% 773
2021
Q4 		– Sell
-44,509
Closed -$1.47M – 2223
2021
Q3 		$1.47M Buy
+44,509
New +$1.73M 0.01% 1216
2020
Q4 		– Sell
-33,268
Closed -$2.37M – 1320
2020
Q3 		$2.37M Buy
+33,268
New +$2.59M 0.02% 794
2018
Q2 		– Sell
-14,050
Closed -$34K – 1774
2018
Q1 		$34K Buy
+14,050
New +$42.1K ﹤0.01% 1871

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dmitry Balyasny's AXSM Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 76,250 shares worth $18.7M. The stake represents 0.02% of the portfolio and ranks #753 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in AXSM as recently as Q1 2025.

Dmitry Balyasny first reported a position in AXSM in Q1 2018 and has held it in 9 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Dmitry Balyasny held 76,250 shares of Axsome Therapeutics worth $18.7M as of Q2 2026.
  • Axsome Therapeutics was a new Dmitry Balyasny position in Q2 2026.
  • Axsome Therapeutics made up 0.02% of Dmitry Balyasny's portfolio in Q2 2026, its #753 holding.
  • Dmitry Balyasny first reported a position in Axsome Therapeutics in Q1 2018 and has held it in 9 quarters since.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.